nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—PTGS1—kidney cancer	0.252	1	CbGaD
Nateglinide—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.0417	0.0762	CbGbCtD
Nateglinide—CYP3A7—Temsirolimus—kidney cancer	0.0417	0.0762	CbGbCtD
Nateglinide—UGT1A9—Sorafenib—kidney cancer	0.0383	0.0699	CbGbCtD
Nateglinide—ORM1—Erlotinib—kidney cancer	0.0347	0.0634	CbGbCtD
Nateglinide—ABCC4—Sorafenib—kidney cancer	0.032	0.0585	CbGbCtD
Nateglinide—CYP3A5—Temsirolimus—kidney cancer	0.0313	0.0572	CbGbCtD
Nateglinide—ABCC4—Sunitinib—kidney cancer	0.0259	0.0474	CbGbCtD
Nateglinide—CYP2D6—Temsirolimus—kidney cancer	0.0192	0.0351	CbGbCtD
Nateglinide—CYP3A4—Everolimus—kidney cancer	0.0181	0.033	CbGbCtD
Nateglinide—ALB—Erlotinib—kidney cancer	0.0146	0.0267	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.0143	0.0262	CbGbCtD
Nateglinide—CYP3A7—Paclitaxel—kidney cancer	0.0143	0.0262	CbGbCtD
Nateglinide—CYP3A7—Sorafenib—kidney cancer	0.0127	0.0232	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.0127	0.0232	CbGbCtD
Nateglinide—CYP3A7—Vincristine—kidney cancer	0.0123	0.0226	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.0123	0.0226	CbGbCtD
Nateglinide—CYP3A4—Temsirolimus—kidney cancer	0.0122	0.0223	CbGbCtD
Nateglinide—CYP3A5—Erlotinib—kidney cancer	0.0117	0.0214	CbGbCtD
Nateglinide—CYP2C9—Capecitabine—kidney cancer	0.0115	0.021	CbGbCtD
Nateglinide—CYP3A5—Paclitaxel—kidney cancer	0.0107	0.0196	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.0103	0.0188	CbGbCtD
Nateglinide—CYP3A7—Sunitinib—kidney cancer	0.0103	0.0188	CbGbCtD
Nateglinide—CYP2D6—Pazopanib—kidney cancer	0.0101	0.0184	CbGbCtD
Nateglinide—CYP3A5—Sorafenib—kidney cancer	0.00954	0.0174	CbGbCtD
Nateglinide—CYP3A5—Vincristine—kidney cancer	0.00926	0.0169	CbGbCtD
Nateglinide—CYP3A5—Sunitinib—kidney cancer	0.00773	0.0141	CbGbCtD
Nateglinide—CYP2C9—Paclitaxel—kidney cancer	0.0072	0.0132	CbGbCtD
Nateglinide—CYP2D6—Erlotinib—kidney cancer	0.00719	0.0131	CbGbCtD
Nateglinide—CYP3A4—Pazopanib—kidney cancer	0.00641	0.0117	CbGbCtD
Nateglinide—CYP2C9—Sorafenib—kidney cancer	0.0064	0.0117	CbGbCtD
Nateglinide—CYP2D6—Sorafenib—kidney cancer	0.00585	0.0107	CbGbCtD
Nateglinide—CYP2D6—Vinblastine—kidney cancer	0.00578	0.0106	CbGbCtD
Nateglinide—CYP3A4—Erlotinib—kidney cancer	0.00457	0.00836	CbGbCtD
Nateglinide—CYP3A4—Paclitaxel—kidney cancer	0.00419	0.00765	CbGbCtD
Nateglinide—PPARG—nephron—kidney cancer	0.00406	0.11	CbGeAlD
Nateglinide—CYP3A4—Sorafenib—kidney cancer	0.00372	0.0068	CbGbCtD
Nateglinide—CYP3A4—Vinblastine—kidney cancer	0.00367	0.00671	CbGbCtD
Nateglinide—CYP3A4—Vincristine—kidney cancer	0.00361	0.0066	CbGbCtD
Nateglinide—CYP2D6—Doxorubicin—kidney cancer	0.00355	0.00649	CbGbCtD
Nateglinide—CYP3A4—Sunitinib—kidney cancer	0.00301	0.00551	CbGbCtD
Nateglinide—CYP3A4—Doxorubicin—kidney cancer	0.00226	0.00412	CbGbCtD
Nateglinide—PPARG—Everolimus—Temsirolimus—kidney cancer	0.00203	1	CbGdCrCtD
Nateglinide—CYP2C9—urine—kidney cancer	0.0019	0.0516	CbGeAlD
Nateglinide—UGT1A9—renal system—kidney cancer	0.00162	0.0438	CbGeAlD
Nateglinide—UGT1A9—kidney—kidney cancer	0.00156	0.0423	CbGeAlD
Nateglinide—CYP3A4—urine—kidney cancer	0.00145	0.0393	CbGeAlD
Nateglinide—CYP2D6—urine—kidney cancer	0.00143	0.0387	CbGeAlD
Nateglinide—SLC22A6—nephron tubule—kidney cancer	0.00132	0.0357	CbGeAlD
Nateglinide—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.00126	0.0341	CbGeAlD
Nateglinide—SLC22A6—cortex of kidney—kidney cancer	0.00113	0.0305	CbGeAlD
Nateglinide—SLC15A1—nephron tubule—kidney cancer	0.0011	0.0297	CbGeAlD
Nateglinide—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.00108	0.0292	CbGeAlD
Nateglinide—ABCC8—renal system—kidney cancer	0.00104	0.0282	CbGeAlD
Nateglinide—ABCC8—kidney—kidney cancer	0.00101	0.0273	CbGeAlD
Nateglinide—SLC15A1—renal system—kidney cancer	0.000997	0.027	CbGeAlD
Nateglinide—SLC15A1—kidney—kidney cancer	0.000964	0.0261	CbGeAlD
Nateglinide—SLC16A1—renal system—kidney cancer	0.000949	0.0257	CbGeAlD
Nateglinide—SLC16A1—kidney—kidney cancer	0.000917	0.0248	CbGeAlD
Nateglinide—SLC16A1—gonad—kidney cancer	0.000851	0.023	CbGeAlD
Nateglinide—SLC16A1—cardiac atrium—kidney cancer	0.00085	0.023	CbGeAlD
Nateglinide—PPARG—renal system—kidney cancer	0.000796	0.0215	CbGeAlD
Nateglinide—ABCC4—nephron tubule—kidney cancer	0.000795	0.0215	CbGeAlD
Nateglinide—PPARG—kidney—kidney cancer	0.000769	0.0208	CbGeAlD
Nateglinide—ABCC4—renal system—kidney cancer	0.000723	0.0196	CbGeAlD
Nateglinide—ABCC4—kidney—kidney cancer	0.000699	0.0189	CbGeAlD
Nateglinide—SLC15A2—nephron tubule—kidney cancer	0.000686	0.0186	CbGeAlD
Nateglinide—ABCC4—cortex of kidney—kidney cancer	0.00068	0.0184	CbGeAlD
Nateglinide—SLC15A2—renal system—kidney cancer	0.000623	0.0169	CbGeAlD
Nateglinide—SLC15A2—kidney—kidney cancer	0.000602	0.0163	CbGeAlD
Nateglinide—SLC15A2—cortex of kidney—kidney cancer	0.000587	0.0159	CbGeAlD
Nateglinide—CYP3A5—nephron tubule—kidney cancer	0.000521	0.0141	CbGeAlD
Nateglinide—Lacosamide—CA9—kidney cancer	0.000511	0.18	CrCbGaD
Nateglinide—Ramipril—BCHE—kidney cancer	0.00051	0.18	CrCbGaD
Nateglinide—CYP3A5—renal system—kidney cancer	0.000474	0.0128	CbGeAlD
Nateglinide—Lacosamide—CA2—kidney cancer	0.00046	0.162	CrCbGaD
Nateglinide—CYP3A5—kidney—kidney cancer	0.000458	0.0124	CbGeAlD
Nateglinide—CYP3A5—cortex of kidney—kidney cancer	0.000446	0.0121	CbGeAlD
Nateglinide—PTGS1—renal system—kidney cancer	0.000426	0.0115	CbGeAlD
Nateglinide—Urine output increased—Capecitabine—kidney cancer	0.000416	0.00442	CcSEcCtD
Nateglinide—Bortezomib—PTGS1—kidney cancer	0.000414	0.146	CrCbGaD
Nateglinide—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.000414	0.0044	CcSEcCtD
Nateglinide—Fatigue—Temsirolimus—kidney cancer	0.000414	0.00439	CcSEcCtD
Nateglinide—Oedema peripheral—Sunitinib—kidney cancer	0.000413	0.00439	CcSEcCtD
Nateglinide—Erythema multiforme—Sorafenib—kidney cancer	0.000412	0.00438	CcSEcCtD
Nateglinide—PTGS1—kidney—kidney cancer	0.000411	0.0111	CbGeAlD
Nateglinide—Tremor—Everolimus—kidney cancer	0.00041	0.00435	CcSEcCtD
Nateglinide—Back pain—Erlotinib—kidney cancer	0.000408	0.00433	CcSEcCtD
Nateglinide—Dyspepsia—Pazopanib—kidney cancer	0.000398	0.00422	CcSEcCtD
Nateglinide—Erythema multiforme—Sunitinib—kidney cancer	0.000397	0.00421	CcSEcCtD
Nateglinide—Immune system disorder—Sorafenib—kidney cancer	0.000394	0.00418	CcSEcCtD
Nateglinide—Gastrointestinal pain—Temsirolimus—kidney cancer	0.000392	0.00416	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Pazopanib—kidney cancer	0.00039	0.00414	CcSEcCtD
Nateglinide—Fatigue—Pazopanib—kidney cancer	0.00039	0.00414	CcSEcCtD
Nateglinide—Neuropathy peripheral—Vincristine—kidney cancer	0.000387	0.00411	CcSEcCtD
Nateglinide—Palpitations—Everolimus—kidney cancer	0.000386	0.0041	CcSEcCtD
Nateglinide—Cough—Everolimus—kidney cancer	0.000382	0.00405	CcSEcCtD
Nateglinide—PTGS1—cardiac atrium—kidney cancer	0.000381	0.0103	CbGeAlD
Nateglinide—Polyuria—Capecitabine—kidney cancer	0.000381	0.00404	CcSEcCtD
Nateglinide—Malnutrition—Sorafenib—kidney cancer	0.00038	0.00403	CcSEcCtD
Nateglinide—Abdominal pain—Temsirolimus—kidney cancer	0.000379	0.00403	CcSEcCtD
Nateglinide—Bortezomib—CYP1A1—kidney cancer	0.000379	0.133	CrCbGaD
Nateglinide—Sweating—Vincristine—kidney cancer	0.000379	0.00402	CcSEcCtD
Nateglinide—Immune system disorder—Sunitinib—kidney cancer	0.000379	0.00402	CcSEcCtD
Nateglinide—Erythema multiforme—Dactinomycin—kidney cancer	0.000376	0.00399	CcSEcCtD
Nateglinide—Gastrointestinal pain—Pazopanib—kidney cancer	0.00037	0.00392	CcSEcCtD
Nateglinide—Cough—Erlotinib—kidney cancer	0.000368	0.00391	CcSEcCtD
Nateglinide—Neuropathy peripheral—Gemcitabine—kidney cancer	0.000368	0.0039	CcSEcCtD
Nateglinide—Malnutrition—Sunitinib—kidney cancer	0.000365	0.00388	CcSEcCtD
Nateglinide—Sweating—Gemcitabine—kidney cancer	0.000359	0.00382	CcSEcCtD
Nateglinide—Abdominal pain—Pazopanib—kidney cancer	0.000357	0.00379	CcSEcCtD
Nateglinide—Increased appetite—Capecitabine—kidney cancer	0.000356	0.00378	CcSEcCtD
Nateglinide—CYP3A4—renal system—kidney cancer	0.000355	0.00962	CbGeAlD
Nateglinide—Hepatobiliary disease—Gemcitabine—kidney cancer	0.000355	0.00376	CcSEcCtD
Nateglinide—Hypersensitivity—Temsirolimus—kidney cancer	0.000353	0.00375	CcSEcCtD
Nateglinide—Back pain—Sunitinib—kidney cancer	0.000353	0.00375	CcSEcCtD
Nateglinide—Influenza—Paclitaxel—kidney cancer	0.000352	0.00374	CcSEcCtD
Nateglinide—Thirst—Capecitabine—kidney cancer	0.000351	0.00373	CcSEcCtD
Nateglinide—CYP2D6—renal system—kidney cancer	0.00035	0.00947	CbGeAlD
Nateglinide—Hyperhidrosis—Everolimus—kidney cancer	0.000345	0.00366	CcSEcCtD
Nateglinide—Asthenia—Temsirolimus—kidney cancer	0.000344	0.00365	CcSEcCtD
Nateglinide—CYP3A4—kidney—kidney cancer	0.000344	0.0093	CbGeAlD
Nateglinide—Sweating increased—Paclitaxel—kidney cancer	0.000343	0.00364	CcSEcCtD
Nateglinide—Pruritus—Temsirolimus—kidney cancer	0.000339	0.0036	CcSEcCtD
Nateglinide—Bronchitis—Paclitaxel—kidney cancer	0.000339	0.00359	CcSEcCtD
Nateglinide—CYP2D6—kidney—kidney cancer	0.000338	0.00915	CbGeAlD
Nateglinide—Osteoarthritis—Capecitabine—kidney cancer	0.000334	0.00355	CcSEcCtD
Nateglinide—Oedema peripheral—Gemcitabine—kidney cancer	0.000332	0.00352	CcSEcCtD
Nateglinide—Cough—Sorafenib—kidney cancer	0.000331	0.00352	CcSEcCtD
Nateglinide—Diarrhoea—Temsirolimus—kidney cancer	0.000328	0.00348	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Paclitaxel—kidney cancer	0.000327	0.00347	CcSEcCtD
Nateglinide—Arthropathy—Doxorubicin—kidney cancer	0.000326	0.00347	CcSEcCtD
Nateglinide—Asthenia—Pazopanib—kidney cancer	0.000324	0.00344	CcSEcCtD
Nateglinide—Pruritus—Pazopanib—kidney cancer	0.00032	0.00339	CcSEcCtD
Nateglinide—Cough—Sunitinib—kidney cancer	0.000319	0.00338	CcSEcCtD
Nateglinide—Erythema multiforme—Gemcitabine—kidney cancer	0.000318	0.00338	CcSEcCtD
Nateglinide—Dizziness—Temsirolimus—kidney cancer	0.000317	0.00337	CcSEcCtD
Nateglinide—Dyspepsia—Everolimus—kidney cancer	0.000314	0.00333	CcSEcCtD
Nateglinide—Diarrhoea—Pazopanib—kidney cancer	0.000309	0.00328	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Everolimus—kidney cancer	0.000308	0.00327	CcSEcCtD
Nateglinide—Neuropathy peripheral—Paclitaxel—kidney cancer	0.000308	0.00327	CcSEcCtD
Nateglinide—Fatigue—Everolimus—kidney cancer	0.000308	0.00327	CcSEcCtD
Nateglinide—Vomiting—Temsirolimus—kidney cancer	0.000305	0.00324	CcSEcCtD
Nateglinide—Immune system disorder—Gemcitabine—kidney cancer	0.000304	0.00323	CcSEcCtD
Nateglinide—Dyspepsia—Erlotinib—kidney cancer	0.000303	0.00322	CcSEcCtD
Nateglinide—Rash—Temsirolimus—kidney cancer	0.000302	0.00321	CcSEcCtD
Nateglinide—Dermatitis—Temsirolimus—kidney cancer	0.000302	0.00321	CcSEcCtD
Nateglinide—Dizziness—Pazopanib—kidney cancer	0.000299	0.00317	CcSEcCtD
Nateglinide—Back pain—Vincristine—kidney cancer	0.000299	0.00317	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000297	0.00315	CcSEcCtD
Nateglinide—Hepatobiliary disease—Paclitaxel—kidney cancer	0.000297	0.00315	CcSEcCtD
Nateglinide—Fatigue—Erlotinib—kidney cancer	0.000297	0.00315	CcSEcCtD
Nateglinide—Gastrointestinal pain—Vinblastine—kidney cancer	0.000293	0.00311	CcSEcCtD
Nateglinide—Gastrointestinal pain—Everolimus—kidney cancer	0.000292	0.0031	CcSEcCtD
Nateglinide—Influenza—Capecitabine—kidney cancer	0.000289	0.00307	CcSEcCtD
Nateglinide—Vomiting—Pazopanib—kidney cancer	0.000287	0.00305	CcSEcCtD
Nateglinide—Rash—Pazopanib—kidney cancer	0.000285	0.00302	CcSEcCtD
Nateglinide—Nausea—Temsirolimus—kidney cancer	0.000285	0.00302	CcSEcCtD
Nateglinide—Dermatitis—Pazopanib—kidney cancer	0.000285	0.00302	CcSEcCtD
Nateglinide—Back pain—Gemcitabine—kidney cancer	0.000283	0.00301	CcSEcCtD
Nateglinide—Abdominal pain—Vinblastine—kidney cancer	0.000283	0.00301	CcSEcCtD
Nateglinide—Abdominal pain—Everolimus—kidney cancer	0.000282	0.00299	CcSEcCtD
Nateglinide—Gastrointestinal pain—Erlotinib—kidney cancer	0.000282	0.00299	CcSEcCtD
Nateglinide—Sweating increased—Capecitabine—kidney cancer	0.000281	0.00299	CcSEcCtD
Nateglinide—Bronchitis—Capecitabine—kidney cancer	0.000278	0.00295	CcSEcCtD
Nateglinide—Oedema peripheral—Paclitaxel—kidney cancer	0.000278	0.00295	CcSEcCtD
Nateglinide—Dyspepsia—Sorafenib—kidney cancer	0.000273	0.00289	CcSEcCtD
Nateglinide—Abdominal pain—Erlotinib—kidney cancer	0.000272	0.00289	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Capecitabine—kidney cancer	0.000269	0.00285	CcSEcCtD
Nateglinide—Nausea—Pazopanib—kidney cancer	0.000268	0.00285	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000267	0.00284	CcSEcCtD
Nateglinide—Fatigue—Sorafenib—kidney cancer	0.000267	0.00283	CcSEcCtD
Nateglinide—Erythema multiforme—Paclitaxel—kidney cancer	0.000266	0.00283	CcSEcCtD
Nateglinide—Hypersensitivity—Vinblastine—kidney cancer	0.000264	0.0028	CcSEcCtD
Nateglinide—Hypersensitivity—Everolimus—kidney cancer	0.000263	0.00279	CcSEcCtD
Nateglinide—Dyspepsia—Sunitinib—kidney cancer	0.000262	0.00278	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000257	0.00273	CcSEcCtD
Nateglinide—Asthenia—Vinblastine—kidney cancer	0.000257	0.00273	CcSEcCtD
Nateglinide—Fatigue—Sunitinib—kidney cancer	0.000257	0.00273	CcSEcCtD
Nateglinide—Asthenia—Everolimus—kidney cancer	0.000256	0.00272	CcSEcCtD
Nateglinide—Cough—Gemcitabine—kidney cancer	0.000256	0.00271	CcSEcCtD
Nateglinide—Immune system disorder—Paclitaxel—kidney cancer	0.000255	0.0027	CcSEcCtD
Nateglinide—Gastrointestinal pain—Sorafenib—kidney cancer	0.000253	0.00269	CcSEcCtD
Nateglinide—Neuropathy peripheral—Capecitabine—kidney cancer	0.000253	0.00268	CcSEcCtD
Nateglinide—Pruritus—Everolimus—kidney cancer	0.000252	0.00268	CcSEcCtD
Nateglinide—Jaundice—Capecitabine—kidney cancer	0.000251	0.00267	CcSEcCtD
Nateglinide—Asthenia—Erlotinib—kidney cancer	0.000247	0.00262	CcSEcCtD
Nateglinide—Urticaria—Sorafenib—kidney cancer	0.000246	0.00261	CcSEcCtD
Nateglinide—Malnutrition—Paclitaxel—kidney cancer	0.000245	0.0026	CcSEcCtD
Nateglinide—Diarrhoea—Vinblastine—kidney cancer	0.000245	0.0026	CcSEcCtD
Nateglinide—Abdominal pain—Sorafenib—kidney cancer	0.000245	0.0026	CcSEcCtD
Nateglinide—Diarrhoea—Everolimus—kidney cancer	0.000244	0.00259	CcSEcCtD
Nateglinide—Gastrointestinal pain—Sunitinib—kidney cancer	0.000244	0.00259	CcSEcCtD
Nateglinide—Hyperhidrosis—Vincristine—kidney cancer	0.000244	0.00259	CcSEcCtD
Nateglinide—Hepatobiliary disease—Capecitabine—kidney cancer	0.000244	0.00259	CcSEcCtD
Nateglinide—Pruritus—Erlotinib—kidney cancer	0.000244	0.00259	CcSEcCtD
Nateglinide—Fatigue—Dactinomycin—kidney cancer	0.000243	0.00258	CcSEcCtD
Nateglinide—Back pain—Paclitaxel—kidney cancer	0.000237	0.00252	CcSEcCtD
Nateglinide—Dizziness—Vinblastine—kidney cancer	0.000237	0.00251	CcSEcCtD
Nateglinide—Dizziness—Everolimus—kidney cancer	0.000236	0.0025	CcSEcCtD
Nateglinide—Abdominal pain—Sunitinib—kidney cancer	0.000236	0.0025	CcSEcCtD
Nateglinide—Diarrhoea—Erlotinib—kidney cancer	0.000236	0.0025	CcSEcCtD
Nateglinide—Hyperhidrosis—Gemcitabine—kidney cancer	0.000231	0.00245	CcSEcCtD
Nateglinide—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000231	0.00245	CcSEcCtD
Nateglinide—Tremor—Paclitaxel—kidney cancer	0.00023	0.00244	CcSEcCtD
Nateglinide—Increased appetite—Doxorubicin—kidney cancer	0.000229	0.00243	CcSEcCtD
Nateglinide—Hypersensitivity—Sorafenib—kidney cancer	0.000228	0.00242	CcSEcCtD
Nateglinide—Oedema peripheral—Capecitabine—kidney cancer	0.000228	0.00242	CcSEcCtD
Nateglinide—Vomiting—Vinblastine—kidney cancer	0.000228	0.00242	CcSEcCtD
Nateglinide—Dizziness—Erlotinib—kidney cancer	0.000228	0.00242	CcSEcCtD
Nateglinide—Vomiting—Everolimus—kidney cancer	0.000227	0.00241	CcSEcCtD
Nateglinide—Rash—Everolimus—kidney cancer	0.000225	0.00239	CcSEcCtD
Nateglinide—Dermatitis—Everolimus—kidney cancer	0.000225	0.00239	CcSEcCtD
Nateglinide—Abdominal pain—Dactinomycin—kidney cancer	0.000223	0.00237	CcSEcCtD
Nateglinide—Asthenia—Sorafenib—kidney cancer	0.000222	0.00236	CcSEcCtD
Nateglinide—Hypoglycaemia—Doxorubicin—kidney cancer	0.000221	0.00234	CcSEcCtD
Nateglinide—Hypersensitivity—Sunitinib—kidney cancer	0.00022	0.00233	CcSEcCtD
Nateglinide—Pruritus—Sorafenib—kidney cancer	0.000219	0.00233	CcSEcCtD
Nateglinide—Vomiting—Erlotinib—kidney cancer	0.000219	0.00232	CcSEcCtD
Nateglinide—Erythema multiforme—Capecitabine—kidney cancer	0.000219	0.00232	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Vincristine—kidney cancer	0.000218	0.00231	CcSEcCtD
Nateglinide—Fatigue—Vincristine—kidney cancer	0.000217	0.00231	CcSEcCtD
Nateglinide—Rash—Erlotinib—kidney cancer	0.000217	0.0023	CcSEcCtD
Nateglinide—Dermatitis—Erlotinib—kidney cancer	0.000217	0.0023	CcSEcCtD
Nateglinide—Palpitations—Paclitaxel—kidney cancer	0.000217	0.0023	CcSEcCtD
Nateglinide—Osteoarthritis—Doxorubicin—kidney cancer	0.000216	0.00229	CcSEcCtD
Nateglinide—Cough—Paclitaxel—kidney cancer	0.000214	0.00227	CcSEcCtD
Nateglinide—Asthenia—Sunitinib—kidney cancer	0.000214	0.00227	CcSEcCtD
Nateglinide—Nausea—Vinblastine—kidney cancer	0.000213	0.00226	CcSEcCtD
Nateglinide—Nausea—Everolimus—kidney cancer	0.000212	0.00225	CcSEcCtD
Nateglinide—Diarrhoea—Sorafenib—kidney cancer	0.000212	0.00225	CcSEcCtD
Nateglinide—Pruritus—Sunitinib—kidney cancer	0.000211	0.00224	CcSEcCtD
Nateglinide—Immune system disorder—Capecitabine—kidney cancer	0.000209	0.00222	CcSEcCtD
Nateglinide—Hypersensitivity—Dactinomycin—kidney cancer	0.000208	0.00221	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000206	0.00219	CcSEcCtD
Nateglinide—Lisinopril—ABCB1—kidney cancer	0.000206	0.0727	CrCbGaD
Nateglinide—Cilazapril—ABCB1—kidney cancer	0.000206	0.0727	CrCbGaD
Nateglinide—Fatigue—Gemcitabine—kidney cancer	0.000206	0.00219	CcSEcCtD
Nateglinide—Gastrointestinal pain—Vincristine—kidney cancer	0.000206	0.00219	CcSEcCtD
Nateglinide—Dizziness—Sorafenib—kidney cancer	0.000205	0.00217	CcSEcCtD
Nateglinide—Nausea—Erlotinib—kidney cancer	0.000205	0.00217	CcSEcCtD
Nateglinide—Diarrhoea—Sunitinib—kidney cancer	0.000204	0.00216	CcSEcCtD
Nateglinide—Asthenia—Dactinomycin—kidney cancer	0.000202	0.00215	CcSEcCtD
Nateglinide—Malnutrition—Capecitabine—kidney cancer	0.000201	0.00214	CcSEcCtD
Nateglinide—Abdominal pain—Vincristine—kidney cancer	0.000199	0.00212	CcSEcCtD
Nateglinide—Dizziness—Sunitinib—kidney cancer	0.000197	0.00209	CcSEcCtD
Nateglinide—Vomiting—Sorafenib—kidney cancer	0.000197	0.00209	CcSEcCtD
Nateglinide—Rash—Sorafenib—kidney cancer	0.000195	0.00207	CcSEcCtD
Nateglinide—Dermatitis—Sorafenib—kidney cancer	0.000195	0.00207	CcSEcCtD
Nateglinide—Back pain—Capecitabine—kidney cancer	0.000195	0.00207	CcSEcCtD
Nateglinide—Hyperhidrosis—Paclitaxel—kidney cancer	0.000194	0.00205	CcSEcCtD
Nateglinide—Diarrhoea—Dactinomycin—kidney cancer	0.000193	0.00205	CcSEcCtD
Nateglinide—Vomiting—Sunitinib—kidney cancer	0.00019	0.00201	CcSEcCtD
Nateglinide—Tremor—Capecitabine—kidney cancer	0.000189	0.002	CcSEcCtD
Nateglinide—Rash—Sunitinib—kidney cancer	0.000188	0.00199	CcSEcCtD
Nateglinide—Dermatitis—Sunitinib—kidney cancer	0.000188	0.00199	CcSEcCtD
Nateglinide—Influenza—Doxorubicin—kidney cancer	0.000186	0.00198	CcSEcCtD
Nateglinide—Hypersensitivity—Vincristine—kidney cancer	0.000186	0.00197	CcSEcCtD
Nateglinide—Nausea—Sorafenib—kidney cancer	0.000184	0.00195	CcSEcCtD
Nateglinide—Asthenia—Vincristine—kidney cancer	0.000181	0.00192	CcSEcCtD
Nateglinide—Vomiting—Dactinomycin—kidney cancer	0.000179	0.0019	CcSEcCtD
Nateglinide—Bronchitis—Doxorubicin—kidney cancer	0.000179	0.0019	CcSEcCtD
Nateglinide—Palpitations—Capecitabine—kidney cancer	0.000178	0.00189	CcSEcCtD
Nateglinide—Rash—Dactinomycin—kidney cancer	0.000178	0.00189	CcSEcCtD
Nateglinide—Nausea—Sunitinib—kidney cancer	0.000177	0.00188	CcSEcCtD
Nateglinide—Dyspepsia—Paclitaxel—kidney cancer	0.000176	0.00187	CcSEcCtD
Nateglinide—Cough—Capecitabine—kidney cancer	0.000176	0.00186	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000173	0.00184	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000173	0.00183	CcSEcCtD
Nateglinide—Fatigue—Paclitaxel—kidney cancer	0.000173	0.00183	CcSEcCtD
Nateglinide—Diarrhoea—Vincristine—kidney cancer	0.000172	0.00183	CcSEcCtD
Nateglinide—Asthenia—Gemcitabine—kidney cancer	0.000172	0.00182	CcSEcCtD
Nateglinide—Pruritus—Gemcitabine—kidney cancer	0.000169	0.0018	CcSEcCtD
Nateglinide—Nausea—Dactinomycin—kidney cancer	0.000168	0.00178	CcSEcCtD
Nateglinide—Dizziness—Vincristine—kidney cancer	0.000167	0.00177	CcSEcCtD
Nateglinide—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000164	0.00174	CcSEcCtD
Nateglinide—Diarrhoea—Gemcitabine—kidney cancer	0.000164	0.00174	CcSEcCtD
Nateglinide—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000163	0.00173	CcSEcCtD
Nateglinide—Jaundice—Doxorubicin—kidney cancer	0.000162	0.00172	CcSEcCtD
Nateglinide—Vomiting—Vincristine—kidney cancer	0.00016	0.0017	CcSEcCtD
Nateglinide—Sweating—Doxorubicin—kidney cancer	0.000159	0.00169	CcSEcCtD
Nateglinide—Urticaria—Paclitaxel—kidney cancer	0.000159	0.00169	CcSEcCtD
Nateglinide—Rash—Vincristine—kidney cancer	0.000159	0.00169	CcSEcCtD
Nateglinide—Hyperhidrosis—Capecitabine—kidney cancer	0.000159	0.00169	CcSEcCtD
Nateglinide—Dermatitis—Vincristine—kidney cancer	0.000159	0.00169	CcSEcCtD
Nateglinide—Abdominal pain—Paclitaxel—kidney cancer	0.000158	0.00168	CcSEcCtD
Nateglinide—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000157	0.00167	CcSEcCtD
Nateglinide—Vomiting—Gemcitabine—kidney cancer	0.000152	0.00161	CcSEcCtD
Nateglinide—Enalapril—ABCB1—kidney cancer	0.000151	0.0533	CrCbGaD
Nateglinide—Rash—Gemcitabine—kidney cancer	0.000151	0.0016	CcSEcCtD
Nateglinide—Dermatitis—Gemcitabine—kidney cancer	0.000151	0.0016	CcSEcCtD
Nateglinide—Nausea—Vincristine—kidney cancer	0.00015	0.00159	CcSEcCtD
Nateglinide—Hypersensitivity—Paclitaxel—kidney cancer	0.000148	0.00157	CcSEcCtD
Nateglinide—Oedema peripheral—Doxorubicin—kidney cancer	0.000147	0.00156	CcSEcCtD
Nateglinide—Dyspepsia—Capecitabine—kidney cancer	0.000145	0.00154	CcSEcCtD
Nateglinide—Asthenia—Paclitaxel—kidney cancer	0.000144	0.00152	CcSEcCtD
Nateglinide—Nausea—Gemcitabine—kidney cancer	0.000142	0.00151	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000142	0.00151	CcSEcCtD
Nateglinide—Fatigue—Capecitabine—kidney cancer	0.000142	0.0015	CcSEcCtD
Nateglinide—Pruritus—Paclitaxel—kidney cancer	0.000142	0.0015	CcSEcCtD
Nateglinide—Erythema multiforme—Doxorubicin—kidney cancer	0.000141	0.0015	CcSEcCtD
Nateglinide—Diarrhoea—Paclitaxel—kidney cancer	0.000137	0.00145	CcSEcCtD
Nateglinide—Immune system disorder—Doxorubicin—kidney cancer	0.000135	0.00143	CcSEcCtD
Nateglinide—Gastrointestinal pain—Capecitabine—kidney cancer	0.000134	0.00143	CcSEcCtD
Nateglinide—Dizziness—Paclitaxel—kidney cancer	0.000132	0.00141	CcSEcCtD
Nateglinide—Urticaria—Capecitabine—kidney cancer	0.000131	0.00139	CcSEcCtD
Nateglinide—Abdominal pain—Capecitabine—kidney cancer	0.00013	0.00138	CcSEcCtD
Nateglinide—Malnutrition—Doxorubicin—kidney cancer	0.00013	0.00138	CcSEcCtD
Nateglinide—Vomiting—Paclitaxel—kidney cancer	0.000127	0.00135	CcSEcCtD
Nateglinide—Rash—Paclitaxel—kidney cancer	0.000126	0.00134	CcSEcCtD
Nateglinide—Dermatitis—Paclitaxel—kidney cancer	0.000126	0.00134	CcSEcCtD
Nateglinide—Back pain—Doxorubicin—kidney cancer	0.000126	0.00133	CcSEcCtD
Nateglinide—Hypersensitivity—Capecitabine—kidney cancer	0.000121	0.00128	CcSEcCtD
Nateglinide—Nausea—Paclitaxel—kidney cancer	0.000119	0.00126	CcSEcCtD
Nateglinide—Asthenia—Capecitabine—kidney cancer	0.000118	0.00125	CcSEcCtD
Nateglinide—Pruritus—Capecitabine—kidney cancer	0.000116	0.00123	CcSEcCtD
Nateglinide—Palpitations—Doxorubicin—kidney cancer	0.000115	0.00122	CcSEcCtD
Nateglinide—Cough—Doxorubicin—kidney cancer	0.000113	0.0012	CcSEcCtD
Nateglinide—Diarrhoea—Capecitabine—kidney cancer	0.000112	0.00119	CcSEcCtD
Nateglinide—Dizziness—Capecitabine—kidney cancer	0.000109	0.00115	CcSEcCtD
Nateglinide—Vomiting—Capecitabine—kidney cancer	0.000104	0.00111	CcSEcCtD
Nateglinide—Rash—Capecitabine—kidney cancer	0.000104	0.0011	CcSEcCtD
Nateglinide—Dermatitis—Capecitabine—kidney cancer	0.000104	0.0011	CcSEcCtD
Nateglinide—Hyperhidrosis—Doxorubicin—kidney cancer	0.000102	0.00109	CcSEcCtD
Nateglinide—Nausea—Capecitabine—kidney cancer	9.76e-05	0.00104	CcSEcCtD
Nateglinide—Dyspepsia—Doxorubicin—kidney cancer	9.32e-05	0.00099	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Doxorubicin—kidney cancer	9.14e-05	0.000971	CcSEcCtD
Nateglinide—Fatigue—Doxorubicin—kidney cancer	9.13e-05	0.000969	CcSEcCtD
Nateglinide—Gastrointestinal pain—Doxorubicin—kidney cancer	8.66e-05	0.000919	CcSEcCtD
Nateglinide—Urticaria—Doxorubicin—kidney cancer	8.41e-05	0.000893	CcSEcCtD
Nateglinide—Abdominal pain—Doxorubicin—kidney cancer	8.37e-05	0.000889	CcSEcCtD
Nateglinide—Hypersensitivity—Doxorubicin—kidney cancer	7.8e-05	0.000828	CcSEcCtD
Nateglinide—Asthenia—Doxorubicin—kidney cancer	7.6e-05	0.000807	CcSEcCtD
Nateglinide—Pruritus—Doxorubicin—kidney cancer	7.49e-05	0.000795	CcSEcCtD
Nateglinide—Diarrhoea—Doxorubicin—kidney cancer	7.25e-05	0.000769	CcSEcCtD
Nateglinide—Dizziness—Doxorubicin—kidney cancer	7e-05	0.000743	CcSEcCtD
Nateglinide—Vomiting—Doxorubicin—kidney cancer	6.73e-05	0.000715	CcSEcCtD
Nateglinide—Rash—Doxorubicin—kidney cancer	6.68e-05	0.000709	CcSEcCtD
Nateglinide—Dermatitis—Doxorubicin—kidney cancer	6.67e-05	0.000708	CcSEcCtD
Nateglinide—Nausea—Doxorubicin—kidney cancer	6.29e-05	0.000668	CcSEcCtD
Nateglinide—PTGS1—Metabolism—ITPR2—kidney cancer	1.27e-05	0.000198	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ALDH1A1—kidney cancer	1.27e-05	0.000197	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ACY1—kidney cancer	1.25e-05	0.000194	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—BCHE—kidney cancer	1.24e-05	0.000193	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—IGF2—kidney cancer	1.24e-05	0.000193	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—FH—kidney cancer	1.23e-05	0.000191	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—APRT—kidney cancer	1.23e-05	0.000191	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—SLC5A5—kidney cancer	1.23e-05	0.00019	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—FH—kidney cancer	1.22e-05	0.00019	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—APRT—kidney cancer	1.22e-05	0.00019	CbGpPWpGaD
Nateglinide—ALB—Metabolism—SLC5A3—kidney cancer	1.22e-05	0.000189	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PGK1—kidney cancer	1.22e-05	0.000189	CbGpPWpGaD
Nateglinide—SLC16A1—Hemostasis—PIK3CA—kidney cancer	1.21e-05	0.000187	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CA9—kidney cancer	1.2e-05	0.000186	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—GSTT1—kidney cancer	1.2e-05	0.000186	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—ACHE—kidney cancer	1.2e-05	0.000186	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.2e-05	0.000185	CbGpPWpGaD
Nateglinide—ALB—Metabolism—LDHB—kidney cancer	1.19e-05	0.000185	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—IL2—kidney cancer	1.19e-05	0.000184	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—SLC2A1—kidney cancer	1.18e-05	0.000184	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—VEGFA—kidney cancer	1.18e-05	0.000183	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.17e-05	0.000182	CbGpPWpGaD
Nateglinide—PPARG—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.17e-05	0.000181	CbGpPWpGaD
Nateglinide—SLC16A1—Hemostasis—TP53—kidney cancer	1.17e-05	0.000181	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—ACHE—kidney cancer	1.16e-05	0.00018	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—GSTT1—kidney cancer	1.16e-05	0.00018	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GPC3—kidney cancer	1.16e-05	0.00018	CbGpPWpGaD
Nateglinide—PPARG—Generic Transcription Pathway—MYC—kidney cancer	1.15e-05	0.000179	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—VEGFA—kidney cancer	1.15e-05	0.000178	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—GSTP1—kidney cancer	1.15e-05	0.000178	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GPC3—kidney cancer	1.15e-05	0.000178	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.15e-05	0.000178	CbGpPWpGaD
Nateglinide—SLC22A6—Transmembrane transport of small molecules—RAF1—kidney cancer	1.14e-05	0.000176	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—SCARB1—kidney cancer	1.14e-05	0.000176	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CA2—kidney cancer	1.13e-05	0.000175	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTGS1—kidney cancer	1.12e-05	0.000174	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CA2—kidney cancer	1.12e-05	0.000173	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—MAPK3—kidney cancer	1.12e-05	0.000173	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PSMD7—kidney cancer	1.1e-05	0.000171	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—SCARB1—kidney cancer	1.1e-05	0.000171	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ALAD—kidney cancer	1.1e-05	0.00017	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ALAD—kidney cancer	1.09e-05	0.000169	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—MAPK3—kidney cancer	1.09e-05	0.000169	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—ABCB1—kidney cancer	1.09e-05	0.000169	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ST3GAL2—kidney cancer	1.07e-05	0.000166	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PSMD7—kidney cancer	1.07e-05	0.000166	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PDHB—kidney cancer	1.06e-05	0.000165	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ST3GAL2—kidney cancer	1.06e-05	0.000165	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—MAPK1—kidney cancer	1.06e-05	0.000165	CbGpPWpGaD
Nateglinide—CYP3A4—Biological oxidations—POMC—kidney cancer	1.06e-05	0.000164	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—GSTM1—kidney cancer	1.06e-05	0.000164	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ALDH1A1—kidney cancer	1.05e-05	0.000163	CbGpPWpGaD
Nateglinide—ALB—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.05e-05	0.000162	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—BCHE—kidney cancer	1.04e-05	0.000162	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—POMC—kidney cancer	1.04e-05	0.000162	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ALDH1A1—kidney cancer	1.04e-05	0.000161	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—MAPK1—kidney cancer	1.04e-05	0.000161	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CA9—kidney cancer	1.04e-05	0.000161	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—SLC5A5—kidney cancer	1.03e-05	0.00016	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CRABP1—kidney cancer	1.02e-05	0.000158	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—BCHE—kidney cancer	1.01e-05	0.000157	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.01e-05	0.000157	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—POMC—kidney cancer	1.01e-05	0.000157	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	1.01e-05	0.000157	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SLC5A3—kidney cancer	1.01e-05	0.000156	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PGK1—kidney cancer	1.01e-05	0.000156	CbGpPWpGaD
Nateglinide—PPARG—Developmental Biology—KRAS—kidney cancer	1e-05	0.000156	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1e-05	0.000155	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—CYP1A1—kidney cancer	1e-05	0.000155	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CCBL1—kidney cancer	1e-05	0.000155	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—SLC5A5—kidney cancer	1e-05	0.000155	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PGK1—kidney cancer	9.97e-06	0.000155	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SLC5A3—kidney cancer	9.97e-06	0.000155	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—SLC2A1—kidney cancer	9.96e-06	0.000154	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—POMC—kidney cancer	9.96e-06	0.000154	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—GSTP1—kidney cancer	9.88e-06	0.000153	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—LDHB—kidney cancer	9.86e-06	0.000153	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—KRAS—kidney cancer	9.78e-06	0.000152	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—LDHB—kidney cancer	9.78e-06	0.000152	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—SLC2A1—kidney cancer	9.66e-06	0.00015	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	9.56e-06	0.000148	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ITPR2—kidney cancer	9.5e-06	0.000147	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	9.37e-06	0.000145	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—ABCB1—kidney cancer	9.35e-06	0.000145	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	9.09e-06	0.000141	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—GSTM1—kidney cancer	9.08e-06	0.000141	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—PIK3CA—kidney cancer	8.99e-06	0.000139	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CRABP1—kidney cancer	8.8e-06	0.000137	CbGpPWpGaD
Nateglinide—ABCC4—Hemostasis—TP53—kidney cancer	8.7e-06	0.000135	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PPAT—kidney cancer	8.67e-06	0.000134	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GLIPR1—kidney cancer	8.67e-06	0.000134	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTT1—kidney cancer	8.67e-06	0.000134	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ACHE—kidney cancer	8.67e-06	0.000134	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—CYP1A1—kidney cancer	8.61e-06	0.000133	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CA9—kidney cancer	8.55e-06	0.000133	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CA9—kidney cancer	8.48e-06	0.000131	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PTGS2—kidney cancer	8.31e-06	0.000129	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—GSTP1—kidney cancer	8.31e-06	0.000129	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	8.28e-06	0.000128	CbGpPWpGaD
Nateglinide—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	8.23e-06	0.000128	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—SCARB1—kidney cancer	8.2e-06	0.000127	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ITPR2—kidney cancer	8.19e-06	0.000127	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.17e-06	0.000127	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTGS1—kidney cancer	8.12e-06	0.000126	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—FH—kidney cancer	8.06e-06	0.000125	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—APRT—kidney cancer	8.06e-06	0.000125	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PTGS2—kidney cancer	8.06e-06	0.000125	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—GSTP1—kidney cancer	8.06e-06	0.000125	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PSMD7—kidney cancer	7.97e-06	0.000123	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PTGS2—kidney cancer	7.95e-06	0.000123	CbGpPWpGaD
Nateglinide—ALB—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	7.89e-06	0.000122	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—ABCB1—kidney cancer	7.87e-06	0.000122	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—GSTM1—kidney cancer	7.64e-06	0.000118	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—ABCB1—kidney cancer	7.63e-06	0.000118	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GPC3—kidney cancer	7.58e-06	0.000118	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—BCHE—kidney cancer	7.55e-06	0.000117	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	7.55e-06	0.000117	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—POMC—kidney cancer	7.47e-06	0.000116	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTT1—kidney cancer	7.46e-06	0.000116	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ACHE—kidney cancer	7.46e-06	0.000116	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—SLC5A5—kidney cancer	7.46e-06	0.000116	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—GSTM1—kidney cancer	7.4e-06	0.000115	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CA2—kidney cancer	7.38e-06	0.000114	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CRABP1—kidney cancer	7.27e-06	0.000113	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PTEN—kidney cancer	7.25e-06	0.000112	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—CYP1A1—kidney cancer	7.24e-06	0.000112	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CRABP1—kidney cancer	7.21e-06	0.000112	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—SLC2A1—kidney cancer	7.2e-06	0.000112	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ALAD—kidney cancer	7.19e-06	0.000111	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.07e-06	0.00011	CbGpPWpGaD
Nateglinide—ALB—Metabolism—SCARB1—kidney cancer	7.07e-06	0.00011	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PTEN—kidney cancer	7.03e-06	0.000109	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—CYP1A1—kidney cancer	7.02e-06	0.000109	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ST3GAL2—kidney cancer	7.02e-06	0.000109	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTGS1—kidney cancer	6.99e-06	0.000108	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PTEN—kidney cancer	6.93e-06	0.000107	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PSMD7—kidney cancer	6.86e-06	0.000106	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ALDH1A1—kidney cancer	6.86e-06	0.000106	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—RAF1—kidney cancer	6.83e-06	0.000106	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ITPR2—kidney cancer	6.76e-06	0.000105	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ITPR2—kidney cancer	6.7e-06	0.000104	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PGK1—kidney cancer	6.57e-06	0.000102	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC5A3—kidney cancer	6.57e-06	0.000102	CbGpPWpGaD
Nateglinide—ALB—Metabolism—BCHE—kidney cancer	6.5e-06	0.000101	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—LDHB—kidney cancer	6.45e-06	0.0001	CbGpPWpGaD
Nateglinide—ALB—Metabolism—SLC5A5—kidney cancer	6.42e-06	9.96e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—POMC—kidney cancer	6.42e-06	9.95e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—SLC2A1—kidney cancer	6.2e-06	9.62e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.18e-06	9.58e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTT1—kidney cancer	6.16e-06	9.55e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ACHE—kidney cancer	6.16e-06	9.55e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—IL2—kidney cancer	6.13e-06	9.5e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ACHE—kidney cancer	6.11e-06	9.47e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTT1—kidney cancer	6.11e-06	9.47e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.02e-06	9.33e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTP1—kidney cancer	6.01e-06	9.31e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PTGS2—kidney cancer	5.96e-06	9.24e-05	CbGpPWpGaD
Nateglinide—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	5.92e-06	9.17e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SCARB1—kidney cancer	5.83e-06	9.04e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SCARB1—kidney cancer	5.78e-06	8.97e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTGS1—kidney cancer	5.78e-06	8.95e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.77e-06	8.94e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTGS1—kidney cancer	5.73e-06	8.88e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—MAPK3—kidney cancer	5.71e-06	8.85e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—ABCB1—kidney cancer	5.69e-06	8.82e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PSMD7—kidney cancer	5.66e-06	8.78e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PSMD7—kidney cancer	5.61e-06	8.7e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CA9—kidney cancer	5.59e-06	8.67e-05	CbGpPWpGaD
Nateglinide—PPARG—Gene Expression—MYC—kidney cancer	5.55e-06	8.61e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—GSTM1—kidney cancer	5.52e-06	8.56e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—POMC—kidney cancer	5.4e-06	8.37e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—BCHE—kidney cancer	5.37e-06	8.32e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—BCHE—kidney cancer	5.32e-06	8.25e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SLC5A5—kidney cancer	5.3e-06	8.22e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SLC5A5—kidney cancer	5.26e-06	8.15e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.25e-06	8.14e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—CYP1A1—kidney cancer	5.23e-06	8.11e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—POMC—kidney cancer	5.23e-06	8.11e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—VEGFA—kidney cancer	5.21e-06	8.07e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PTEN—kidney cancer	5.2e-06	8.06e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTP1—kidney cancer	5.17e-06	8.02e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—SLC2A1—kidney cancer	5.12e-06	7.94e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PTGS2—kidney cancer	5.12e-06	7.94e-05	CbGpPWpGaD
Nateglinide—ABCC8—Metabolism—PIK3CA—kidney cancer	5.11e-06	7.93e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—SLC2A1—kidney cancer	5.08e-06	7.87e-05	CbGpPWpGaD
Nateglinide—KCNJ11—Metabolism—PIK3CA—kidney cancer	4.96e-06	7.69e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.93e-06	7.64e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—MAPK3—kidney cancer	4.93e-06	7.64e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—ABCB1—kidney cancer	4.9e-06	7.59e-05	CbGpPWpGaD
Nateglinide—SLC16A1—Metabolism—PIK3CA—kidney cancer	4.89e-06	7.58e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—GSTM1—kidney cancer	4.75e-06	7.37e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CRABP1—kidney cancer	4.75e-06	7.37e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—MAPK1—kidney cancer	4.69e-06	7.27e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—CYP1A1—kidney cancer	4.51e-06	6.99e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PTEN—kidney cancer	4.46e-06	6.92e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—KRAS—kidney cancer	4.43e-06	6.86e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ITPR2—kidney cancer	4.42e-06	6.85e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTGS2—kidney cancer	4.31e-06	6.68e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.3e-06	6.66e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTP1—kidney cancer	4.27e-06	6.62e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTP1—kidney cancer	4.24e-06	6.57e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PTGS2—kidney cancer	4.17e-06	6.47e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—PIK3CA—kidney cancer	4.07e-06	6.31e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—ABCB1—kidney cancer	4.04e-06	6.27e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTT1—kidney cancer	4.03e-06	6.25e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ACHE—kidney cancer	4.03e-06	6.25e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—ABCB1—kidney cancer	4.01e-06	6.22e-05	CbGpPWpGaD
Nateglinide—ALB—Hemostasis—TP53—kidney cancer	3.93e-06	6.1e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—GSTM1—kidney cancer	3.93e-06	6.09e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—POMC—kidney cancer	3.9e-06	6.05e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—GSTM1—kidney cancer	3.89e-06	6.03e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SCARB1—kidney cancer	3.81e-06	5.91e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTGS1—kidney cancer	3.78e-06	5.85e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PTEN—kidney cancer	3.76e-06	5.82e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.72e-06	5.77e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.7e-06	5.74e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PSMD7—kidney cancer	3.7e-06	5.74e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—CYP1A1—kidney cancer	3.69e-06	5.72e-05	CbGpPWpGaD
Nateglinide—PPARG—Metabolism—PIK3CA—kidney cancer	3.67e-06	5.68e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PTEN—kidney cancer	3.64e-06	5.64e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—BCHE—kidney cancer	3.51e-06	5.44e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.47e-06	5.38e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—POMC—kidney cancer	3.36e-06	5.21e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.35e-06	5.19e-05	CbGpPWpGaD
Nateglinide—UGT1A9—Metabolism—PIK3CA—kidney cancer	3.15e-06	4.88e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTGS2—kidney cancer	3.11e-06	4.83e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.03e-06	4.7e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTP1—kidney cancer	2.79e-06	4.33e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—POMC—kidney cancer	2.77e-06	4.3e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—POMC—kidney cancer	2.75e-06	4.26e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PTEN—kidney cancer	2.71e-06	4.21e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTGS2—kidney cancer	2.68e-06	4.16e-05	CbGpPWpGaD
Nateglinide—CYP3A7—Metabolism—PIK3CA—kidney cancer	2.65e-06	4.11e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—ABCB1—kidney cancer	2.64e-06	4.1e-05	CbGpPWpGaD
Nateglinide—PTGS1—Metabolism—PIK3CA—kidney cancer	2.57e-06	3.98e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—GSTM1—kidney cancer	2.57e-06	3.98e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.43e-06	3.77e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PTEN—kidney cancer	2.34e-06	3.62e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTGS2—kidney cancer	2.21e-06	3.43e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTGS2—kidney cancer	2.19e-06	3.4e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PTEN—kidney cancer	1.93e-06	2.99e-05	CbGpPWpGaD
Nateglinide—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.91e-06	2.97e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PTEN—kidney cancer	1.91e-06	2.97e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—POMC—kidney cancer	1.81e-06	2.81e-05	CbGpPWpGaD
Nateglinide—ALB—Metabolism—PIK3CA—kidney cancer	1.65e-06	2.56e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTGS2—kidney cancer	1.45e-06	2.24e-05	CbGpPWpGaD
Nateglinide—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.36e-06	2.11e-05	CbGpPWpGaD
Nateglinide—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.35e-06	2.09e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PTEN—kidney cancer	1.26e-06	1.96e-05	CbGpPWpGaD
Nateglinide—CYP3A4—Metabolism—PIK3CA—kidney cancer	8.9e-07	1.38e-05	CbGpPWpGaD
